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While biologic drugs such as anti-TNFa antibodies and soluble TNFa receptors have made significant impact on human
health, there is an increasing demand for small molecule inhibitors that control TNFa function. The study by Gururaja
et al. highlights the discovery of a class of small molecule TNFa antagonists that inhibit most of the TNFa functions via
blockade of ligand-dependent receptor (TNFaRI) endocytosis, resulting in disruption of TNFaRI/TRADD/RIP1 interactions.
These triazoloquinoxaline (TQ)-based compounds modulate both TNFa-induced survival and apoptotic pathways; such
dual activity makes them unique, since compounds targeting only a subset of TNFa signaling pathways (e.g., IKK and
proteasome inhibitors) increase TNFa-induced cytotoxicity.
Targeting Quorum Sensing as New Antibacterial Strategy
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Bacteria have evolved an elaborate small molecule-based communication system
called quorum sensing (QS). QS plays an important role in mediating bacterial viru-
lence, and it constitutes a newly emerging target for development of antibacterial
agents. Park and colleagues report an immunopharmacotherapeutic approach for
the attenuation of (QS) in the Gram-positive human pathogen Staphylococcus au-
reus. An anti-autoinducer monoclonal antibody was elicited against a rationally
designed hapten and was shown to efficiently inhibit QS in vitro. Importantly, the
anti-autoinducer antibody suppressed S. aureus pathogenicity in an abscess
formation mouse model and provided mice with a complete protection against a le-
thal S. aureus challenge. These findings build a strong foundation for further inves-
tigation of using immunopharmacotherapy for the treatment of bacterial infections in
which the expression of virulence factors is under QS control.
Investigating Complexity of Gold(III)-dithiocarbamato Complexes
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Gold(III)-dithiocarbamato complexes are promising chemotherapeutics able to exert outstanding cytotoxic activity toward
tumor cell lines. Furthermore, they induce a strong downregulation of Bcl-2 and upregulation of Bax proteins and inhibition
of proteasome activity, but only weak perturbations of cell cycle. In the paper by Saggioro et al. the complexes’ mechanism
of action was analyzed by means of cellular, biochemical, and molecular approaches. The authors show that gold(III)-
dithiocarbamato complexes induce cancer cell death through both apoptotic and nonapoptotic mechanisms. A working
model, suggesting that deregulation of the thioredoxin reductase/thioredoxin redox system is a major mechanism involved
in the anticancer activity of the investigated compounds, was proposed and discussed.
Multivalent Interactions with ‘‘Beads on a String’’
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The role of flexibility and adaptability in multivalent binding events is an intrigu-
ing question of molecular recognition with special relevance to glycobiology.
Belitsky et al. have investigated the interactions between self-assembled multi-
valent supramolecular complexes known as pseudopolyrotaxanes and a biva-
lent lectin, galectin-1. The pseudopolyrotaxanes are comprised of lactoside-
displaying cyclodextrin ‘‘beads’’ threaded onto polyviologen ‘‘strings,’’ which
provide a flexible and adaptable presentation of lactoside ligands. These self-
assembled complexes are useful tools for the study of multivalent interac-
tions—and more broadly—suggest that the conceptually related, but often
disparate, fields of supramolecular chemistry and biochemistry have much to
offer each other.Chemistry & Biology 14, October 2007 ª2007 Elsevier Ltd All rights reserved ix
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The ability to specifically target therapeutics and imagingmo-
dalities to tumors is an important goal in biomedicine. Viral
nanoparticles (VNPs) such as cowpea mosaic virus (CPMV)
provide tremendous imaging resolution of normal and tumor
vasculature; however, the particles have significant affinity
for cell-surface proteins. To mask any natural in vivo interac-
tions of CPMV, ‘‘click’’ chemistry was used to attach folic acid
tumor ligands, while redirecting the natural specificity of the
particles by coating the remaining surface of the particles
with polyethylene glycol. The resulting particles demonstrate
that effective retargeting of VNPs may be mediated by small
molecule ligands.
Mechanism-of-Action (MOA) Determination of GMP Synthase
Inhibitors
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Compound mechanism-of-action (MOA) study and target validation are crucial aspects of drug discovery. Using a chemo-
genomics approach, the Candida albicans fitness test, Rodriguez-Suarez and colleagues conducted MOA analyses for
several compounds affecting purine metabolism, and identified a novel antifungal compound (ECC1385) as a potent inhib-
itor of GMP synthase, which is encoded by theGUA1 gene. The authors further demonstrated, in bothCandida albicans and
Aspergillus fumigatus, that genetic inactivation of the GUA1 gene rendered the pathogens completely avirulent in murine
infection models, thus validating GUA1 as an unexpected antifungal target.
Selecting Horseradish Peroxidise Variants via Yeast Surface Display
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The first application of yeast surface display to in vitro selection of
altered enzymatic activity was presented by Lipovsˇek et al. The
use of a eukaryotic organism to display the enzyme under selec-
tion makes possible in vitro evolution of a number of enzymes
that cannot be expressed in a soluble and active form in bacteria,
such as highly disulfide–crosslinked enzymes. In this study, the
authors selected variants of horseradish peroxidase with up to
an 8-fold altered enantioselectivity, including its reversal, from
an active-site-directed library. In contrast, a library of similar size
constructed using error-prone PCR yielded no HRP variants with
a significantly improved enantioselectivity.
Allosteric Inhibition of the RUNX1 and CBFb Interaction
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Numerous inhibitors of enzymatic activity have been developed, but the development of inhibitors of protein-protein inter-
actions has only recently come to the forefront as a viable approach. Allosteric inhibition of such protein-protein interactions
presents a number of advantages, including not having to compete for binding with the partner protein; however, to date
there are very few examples of such inhibitors. Gorczynski et al. have developed novel allosteric small molecule inhibitors of
the binding of RUNX1 to CBFb, two proteins whose translocations play a critical role in the development of acute myeloid
leukemia and acute lymphocytic leukemia.x Chemistry & Biology 14, October 2007 ª2007 Elsevier Ltd All rights reserved
